Related Experiment Video
Updated: May 23, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study.
1Division of Nephrology and Hypertension, Department of Medicine, Weill/Cornell Medical Center, New York Presbyterian Hospital, New York, NY 10021, USA. sjmann@med.cornell.edu
Journal of Clinical Hypertension (Greenwich, Conn.)
|March 31, 2012
Summary
A new algorithm effectively treated resistant hypertension in 89% of patients. This approach simplified management by adjusting diuretics or adding specific blockers, showing promise for future studies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Resistant hypertension poses a significant clinical challenge.
- Current treatment strategies often require complex medication regimens.
Purpose of the Study:
- To evaluate the efficacy of a novel, mechanism-based algorithm for managing resistant hypertension.
- To assess the impact of algorithm-guided interventions on blood pressure control.
Main Methods:
- Retrospective chart review of patients with resistant hypertension.
- Interventions focused on optimizing diuretic regimens (e.g., adding spironolactone) and/or introducing an alpha- and non-metabolized beta-blocker combination.
- Analysis of medication adjustments and blood pressure control rates.
Main Results:
- 24 out of 27 patients (89%) achieved controlled blood pressure.
- Diuretic regimen strengthening was employed in 54% of patients.
- Alpha-/beta-blockade was initiated in 25% of patients, with 21% receiving both interventions.
- Common adjustments included adding potassium-sparing diuretics (67%) and doxazosin (37.5%).
Conclusions:
- The described algorithm offers a simplified and effective approach to resistant hypertension management.
- Algorithm-based treatment significantly improved blood pressure control in this patient cohort.
- Further prospective studies are warranted to validate these findings.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...